Renal Business Today

Clinical & Pharma

Kidney disease patients rely on numerous pharmaceuticals—including erythropoiesis-stimulating agents (ESAs),iron, Vitamin D, phosphate binders and calcium—to ensure proper care. In addition, new clinical research is released on a regular basis by nephrologists and other doctors to advance the field of nephrology.

Low Income Linked to Higher Levels of Kidney Disease in African Americans

NEW YORK—African Americans who live below the poverty line feel the impact beyond basic needs such as food and shelter. Low income is more strongly associated with chronic kidney disease among African Americans than it is among whites, according to a study published in the ...More
November 5, 2012
Posted in News, Clinical & Pharma
Study Results Simultaneously Presented at ASNs Kidney Week

THOUSAND OAKS, Calif.—Amgen announced results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated treatment with Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) ...More
November 5, 2012
Posted in News, Clinical & Pharma
Transplantation Issues: Kidney Donors and Children in Need of Transplants

SAN DIEGO—Three studies presented during the American Society of Nephrology’s (ASN) Annual Kidney Week provide new information related to kidney transplantation—specifically, the post-transplant health of kidney donors and the racial disparities faced by children in need of ...More
November 5, 2012
Posted in News, Clinical & Pharma
Health of Kidney Disease Patients: Diet and Blood Pressure

SAN DIEGO—Three studies presented during the American Society of Nephrology’s (ASN) Annual Kidney Week provide new information on diet and blood pressure in kidney disease patients. ...More
November 1, 2012
Posted in News, Clinical & Pharma
Affymax, Takeda Announce Analyses from Omontys Injection Phase 3 Dialysis Studies Presented at ASN

PALO ALTO, Calif. & DEERFIELD, Ill.—Affymax and Takeda Pharmaceuticals U.S.A. announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated Omontys (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the ...More
November 1, 2012
Posted in News, Clinical & Pharma
Overweight, Obesity in Adolescents Appears Associated with Increased Risk for ESRD Over Time

CHICAGO—Being overweight and obese during adolescence appears related to an increased risk of all-cause treated end-stage renal disease (ESRD) during a 25-year period, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication. ...More
October 30, 2012
Posted in News, Clinical & Pharma
Regardless of Age, Measures of Kidney Function Remain Predictors of Kidney Disease and Death

CHICAGO—In a large, collaborative study that included more than 2 million individuals from around the world, two measures of poor kidney function, low estimated glomerular filtration rate and high albuminuria, were associated with risk of death and end-stage renal disease ...More
October 30, 2012
Posted in News, Clinical & Pharma
Obesity and CKD Complications

CLEVELAND, Ohio—Over one-third of the U.S. population is obese and over 10 percent have chronic kidney disease (CKD) posing enormous burden on the health care system. ...More
October 19, 2012
Posted in Articles, Clinical & Pharma
Damage to Blood Vessel Lining May Account for Kidney Failure Patients' Heart Risks

WASHINGTON—Individuals with kidney failure often develop heart problems, but it’s not clear why. A study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN) provides evidence that their kidneys’ inability to excrete waste products in ...More
October 19, 2012
Posted in News, Clinical & Pharma
New Target for Treating Diabetic Kidney Disease

WASHINGTON—Researchers have discovered a new therapeutic target for diabetic nephropathy, the leading cause of kidney failure. The findings, appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), could help protect the kidney health of ...More
October 19, 2012
Posted in News, Clinical & Pharma